Cel Sci (CVM) Net Cash Flow Growth (5y) (2015 - 2026)
Cel Sci (CVM) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.24% |
| Dec 31, 2025 | -22.30% |
| Sep 30, 2025 | 31.81% |
| Jun 30, 2025 | -15.13% |
| Mar 31, 2025 | -20.53% |
| Dec 31, 2024 | -16.35% |
| Sep 30, 2024 | 43.96% |
| Jun 30, 2024 | -26.51% |
| Mar 31, 2024 | 30.40% |
| Dec 31, 2023 | 24.26% |
| Sep 30, 2023 | -16.26% |
| Jun 30, 2023 | -47.00% |
| Mar 31, 2023 | -60.56% |
| Dec 31, 2022 | -83.02% |
| Sep 30, 2022 | -46.51% |
| Jun 30, 2022 | -83.64% |
| Mar 31, 2022 | -26.96% |
| Dec 31, 2021 | 31.79% |
| Sep 30, 2021 | 15.38% |
| Jun 30, 2021 | 106.38% |